Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 29, 2010
Impax Laboratories Receives Final FDA Approval for Generic Doryx(R) 75 and 100mg Tablets
Dec 16, 2010
GlaxoSmithKline and Impax Pharmaceuticals Enter Global Agreement to Develop and Commercialize a late stage compound for Parkinson's Disease
Dec 03, 2010
Impax Laboratories Confirms Patent Challenge Relating to INTUNIVTM, 4 mg
Nov 29, 2010
Impax Laboratories Confirms Patent Suit Relating to Generic Concerta(R) 54 mg Tablets
Nov 26, 2010
Impax Laboratories to Present at the Piper Jaffray Annual Healthcare Conference
Nov 26, 2010
Impax Laboratories Confirms Patent Challenge Relating to SIMCOR(R) Extended-Release Tablets, 1000/20 mg
Nov 23, 2010
What Patients Should Know About Generic Drugs: A Resource Guide for Pharmacists
PDF format download (opens in new window)
Nov 22, 2010
Impax Confirms Patent Challenge Relating to WELCHOL(R) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet
Nov 22, 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Nov 18, 2010
Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy and Safety in APEX-PD Phase III Study in Treatment of Early Parkinson's Disease
Nov 16, 2010
Impax Laboratories Receives Final FDA Approval for Generic Allegra-D 60mg/120mg Tablets
Nov 05, 2010
Impax Laboratories to Present at the Credit Suisse 19th Annual Healthcare Conference
Nov 02, 2010
Impax Laboratories Reports Growth in Revenue, Profit and Earnings in the Third Quarter 2010
Nov 01, 2010
Impax Laboratories Announces Litigation Against Shire Relating to Supply of Generic Adderall XR(R)
Oct 04, 2010
Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2010 Financial Results
Sep 30, 2010
Impax Laboratories to Present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference
Sep 20, 2010
Amneal Pharmaceuticals to Host Grand Opening of New Glasgow, KY Distribution and Sales Center on
PDF format download (opens in new window)
Sep 15, 2010
Impax Laboratories to Present at the UBS Global Life Sciences Conference
Sep 08, 2010
Impax Laboratories to Present at the Morgan Stanley Global Healthcare Conference
Aug 26, 2010
Amneal Announces FDA Approval For Spironolactone HCL Tablets
PDF format download (opens in new window)
Aug 25, 2010
Impax Pharmaceuticals Completes Enrollment in ADVANCE-PD Phase III Trial of IPX066 in Parkinson's Disease
Aug 20, 2010
Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg
Aug 05, 2010
Impax Laboratories Enters Into Development Agreement with Perrigo
Aug 03, 2010
Impax Laboratories Continues Strong Growth in Revenue, Profit and Earnings in the Second Quarter 2010
Jul 27, 2010
Amneal Pharmaceuticals Receives Five Generics Industry Awards For Customer Value and Service Excellence
PDF format download (opens in new window)
Jul 22, 2010
Impax Laboratories Receives Final FDA Approval for Generic OPANA(R) ER Tablets
Jul 08, 2010
Amneal Appoints Dr. Shankar Hariharan as Chief Scientific Officer/EVP of Specialty Pharmaceuticals
PDF format download (opens in new window)
Jul 08, 2010
Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2010 Financial Results
Jul 02, 2010
Impax Laboratories Confirms Patent Challenge Relating to RENVELA(R), 2.4 g and 0.8 g (For Suspension)
Jun 18, 2010
Impax Laboratories to Present at the Wells Fargo Securities Healthcare Conference
Jun 15, 2010
Amneal Receives FDA Approval for Lorazepam Oral Concentrate, USP
PDF format download (opens in new window)
Jun 08, 2010
Impax Laboratories and Endo Pharmaceuticals Settle Pending Litigation for Opana(R) ER and Announce Development and Co-Promotion Agreement
Jun 07, 2010
Impax Laboratories to Present at Upcoming Investor Conferences on June 10
May 26, 2010
Impax Laboratories Enters Into Development and Supply Agreement with IGI Laboratories
May 25, 2010
Mpax Laboratories Announces Voting Results from 2010 Annual Meeting of Stockholders
May 14, 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Opana(R) ER 5, 7.5, 10, 15, 20, 30 and 40 mg Tablets
May 11, 2010
Impax Laboratories to Present at the Goldman Sachs 31st Annual Global Healthcare Conference
May 10, 2010
Impax Laboratories to Present at the Bank of America Merrill Lynch Health Care Conference
May 08, 2010
Impax Laboratories and Endo Pharmaceuticals Settle Pending Litigation for Opana(R) ER and Announce Development and Co-Promotion Agreement
May 04, 2010
Impax Laboratories Reports Significant Growth for the First Quarter 2010
May 02, 2010
Impax Laboratories to Present at the Deutsche Bank 35th Annual Health Care Conference
Apr 29, 2010
Impax Laboratories Confirms Patent Challenge Relating to Fenoglide(R) 40 and 120 mg Tablets
Apr 19, 2010
Impax Pharmaceuticals Completes Enrollment in APEX-PD Phase III Trial of IPX066 in Parkinson's Disease
Apr 15, 2010
Impax Pharmaceuticals Announces Amendment of Co-Promotion Agreement
Apr 15, 2010
Impax Pharmaceuticals Completes Enrollment in APEX-PD Phase III Trial of IPX066 in Parkinson's Disease
Apr 08, 2010
Allen Chao, Ph.D. Elected to Impax Laboratories Board of Directors
Apr 06, 2010
Impax Laboratories Schedules Conference Call for First Quarter 2010 Financial Results
Mar 17, 2010
Impax Laboratories to Present at the Barclays Capital 2010 Global Healthcare Conference
Mar 15, 2010
Impax Laboratories Confirms Patent Challenge Relating to TRILIPIX(R) Delayed-Release Capsules, 135 mg and 45 mg
Mar 04, 2010
Impax Laboratories to Present at the Cowen & Co. 30th Annual Health Care Conference on March 9, 2010
Mar 02, 2010
Impax Laboratories Receives Final FDA Approval for Generic FLOMAX(R) 0.4mg Capsules and Immediately Commences Shipment
Feb 26, 2010
Impax Laboratories to Appear at the RBC Capital Markets Healthcare Conference on Tuesday, March 2, 2010
Feb 25, 2010
Impax Laboratories Reports Record Growth in Revenue, Net Income and Earnings for the Fourth Quarter and Full Year 2009
Jan 21, 2010
Impax Laboratories Schedules Conference Call for Fourth Quarter and Full Year 2009 Financial Results
Jan 16, 2010
Impax Laboratories to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 15, 2010
Impax Laboratories Confirms Patent Challenge Relating to WELCHOL(R) 625 mg Tablets

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top